Somnoplasty system set for launch in Japan:
This article was originally published in Clinica
Somnus Medical Technologies has received Japanese approval to market its radiofrequency-based Somnoplasty system for treating obstructive sleep apnoea, chronic nasal obstruction and habitual snoring. The control unit and single use disposable devices have already been cleared in the US and will be launched in Japan shortly. Sunnyvale, California-based Somnus said that industry reports have estimated that around 7.5% of Japanese adults aged 18-68 suffer from some form of obstructive sleep apnoea. This is more than twice the rate in the US.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.